ClinicalTrials.gg
CompletedNCT00985959Updated Dec 2, 2013Results posted

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

A Phase 1 interventional study of JNJ-26866138 0.7 mg/m2 and JNJ-26866138 1.0 mg/m2 in Multiple Myeloma, sponsored by Janssen Pharmaceutical K.K.. Completed at 28 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-02.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
49th of 267
101 · median 41
Started
2008
with 21 others
Phase 1
41 of 271
1 open now
Registered
122nd of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 49th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 41 in phase 1, and was the 122nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study in Phase I is to select the recommended dose of bortezomib in combination with melphalan and prednisolone in Japanese participants. In Phase II, to assess the effectiveness and safety of the recommended dose of bortezomib (selected in the phase I portion).

Read the detailed description

This is an open-label (both physician and participant know the intervention), non-randomized (participants are not assigned by chance), multi-center study in untreated multiple myeloma participants who were not candidates for hematopoietic stem cell transplant. This study consists of two parts: Phase I and Phase II. In Phase I, a total of 18 participants will be enrolled ie, 6 patients per dose level (0.7, 1.0 and 1.3 mg/m2) to determine the recommended dose of bortezomib. In Phase II, additional 83 participants will be enrolled. Safety evaluations will include assessment of adverse events, clinical laboratory test, specifically hematological toxicities.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Hematopoietic stem cell transplant
  • HSCT
  • Melphalan
  • Prednisolone
  • Bortezomib
  • JNJ-26866138
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with symptomatic or nonsecretory multiple myeloma
  • Participants who have not received chemotherapy and are not hematopoietic stem cell transplantation candidates
  • Participants with a
  • greater than or equal to 3 months

Exclusion criteria

Exclusion Criteria:

  • Previously received treatment for Multiple Myeloma
  • Greater than or equal to Grade 2 peripheral neuropathy or neuropathic pain
  • Myocardial infarction within 6 months prior to enrollment or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or conduction system abnormalities
  • Patient is known to be seropositive for the (HIV), surface antigen-positive or active infection
  • Active prior diagnosed within the last 5 years
  • Female participant who is pregnant or breast-feeding
  • Participant is enrolled in another clinical research study and/or is receiving an agent
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Phase I: JNJ-26866138 0.7 mg/m2

    JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.

    Drug: JNJ-26866138 0.7 mg/m2 · Drug: Melphalan · Drug: Prednisolone

  • Experimental
    Phase I: JNJ-26866138 1.0 mg/m2

    JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles

    Drug: JNJ-26866138 1.0 mg/m2 · Drug: Melphalan · Drug: Prednisolone

  • Experimental
    Phase I: JNJ-26866138 1.3 mg/m2

    JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles

    Drug: JNJ-26866138 1.3 mg/m2 · Drug: Melphalan · Drug: Prednisolone

  • Experimental
    Phase II: JNJ-26866138 1.3 mg/m2

    JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

    Drug: JNJ-26866138 1.3 mg/m2 · Drug: Melphalan · Drug: Prednisolone

Interventions

  • DrugJNJ-26866138 0.7 mg/m2

    Drug page: Bortezomib

    JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.

    Also known as: bortezomib

  • DrugJNJ-26866138 1.0 mg/m2

    Drug page: Bortezomib

    JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles

    Also known as: bortezomib

  • DrugJNJ-26866138 1.3 mg/m2

    Drug page: Bortezomib

    Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.

    Also known as: bortezomib

  • Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

  • Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)

    Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the participants during 6 weeks of treatment Cycle 1

    Time frame: 6 weeks

  2. Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II

    Response is evaluated as per the criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (Blade et al. 1998). CR: disappearance of the original monoclonal protein from the blood and urine and \<5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks; no increase in the size or number of lytic bone lesions; disappearance of soft tissue plasmacytomas for at least 6 weeks. PR: ≥50% reduction in the level of serum monoclonal protein for at least 2 determinations 6 weeks apart; If present, reduction in 24-hour urinary light chain excretion by either ≥90% or to \<200 mg for at least 2 determinations 6 weeks apart; ≥50% reduction in the size of soft tissue plasmacytomas for at least 6 weeks; no increase in size or number of lytic bone lesions

    Time frame: 54 weeks

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I

    Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 1/Day 25 (JNJ-26866138 alone)

    Time frame: Day 25 of Cycle 1

  2. Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I

    Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 2/Day 4 (combination with melphalan and prednisolone)

    Time frame: Day 4 of Cycle 2

  3. Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I

    Cmax of melphalan at dose of 9 mg/m2 on Cycle 2/Day 4

    Time frame: Day 4 of Cycle 2

  4. Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I

    Cmax of Prednisolone at dose of 60 mg/m2 on Cycle 2/Day 4

    Time frame: Day 4 of Cycle 2

  5. Median Time to First Response - Phase II

    Time to first response is the duartion of time required to achieve first response to treatment

    Time frame: up to 54 weeks

07

Results

Posted Dec 2, 2013

Participant flow

Total 101 participants (Phase I: 18 and Phase II: 83) were enrolled at multiple sites in Japan.

Participant flow — Overall Study
MilestonePhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I and II - JNJ-26866138 1.3 mg/m2 Group
Started6687
Completed3328
Not completed3359
Withdrew: Adverse event0019
Withdrew: Withdrawal by subject008
Withdrew: Progressive disease128
Withdrew: Unrecovered toxicity007
Withdrew: Pneumonitis or pulmonary fibrosis202
Withdrew: Complete response observed over 2 cycles014
Withdrew: Other0011

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)

Dose limiting toxicity defined as an adverse event or adverse drug reaction experienced by the participants during 6 weeks of treatment Cycle 1

Time frame:
6 weeks
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)
ParticipantsPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 Group
Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)001
PrimaryNumber of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II

Response is evaluated as per the criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (Blade et al. 1998). CR: disappearance of the original monoclonal protein from the blood and urine and \<5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks; no increase in the size or number of lytic bone lesions; disappearance of soft tissue plasmacytomas for at least 6 weeks. PR: ≥50% reduction in the level of serum monoclonal protein for at least 2 determinations 6 weeks apart; If present, reduction in 24-hour urinary light chain excretion by either ≥90% or to \<200 mg for at least 2 determinations 6 weeks apart; ≥50% reduction in the size of soft tissue plasmacytomas for at least 6 weeks; no increase in size or number of lytic bone lesions

Time frame:
54 weeks
Reported as:
Number · Participants
Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II
ParticipantsPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 GroupPhase II - JNJ-26866138 1.3 mg/m2 GroupTotal
Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II6 (54.1 to 100.0)5 (35.9 to 99.6)4 (28.4 to 99.5)60 (58.9 to 79.2)71
Statistical analysis
  • Phase II - JNJ-26866138 1.3 mg/m2 Group · Binominal test · p = <0.0001 (Significance level 5% one-tailed. Threshold response rate 35%) · Overall response rate (%): 69.8 · 95% CI 58.9 to 79.2
SecondaryMaximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I

Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 1/Day 25 (JNJ-26866138 alone)

Time frame:
Day 25 of Cycle 1
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I
ng/mLPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 Group
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I45.43 ± 10.08759.42 ± 18.89120.3 ± 24.527
SecondaryMaximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I

Cmax of bortezomib following intravenous administration of JNJ-26866138 at dose of 0.7, 1.0, and 1.3 mg/m2 on Cycle 2/Day 4 (combination with melphalan and prednisolone)

Time frame:
Day 4 of Cycle 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I
ng/mLPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 Group
Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I34.40 ± 5.798669.50 ± 19.45588.87 ± 19.568
SecondaryMaximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I

Cmax of melphalan at dose of 9 mg/m2 on Cycle 2/Day 4

Time frame:
Day 4 of Cycle 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I
ng/mLMelphalan
Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I100.2 ± 49.515
SecondaryMaximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I

Cmax of Prednisolone at dose of 60 mg/m2 on Cycle 2/Day 4

Time frame:
Day 4 of Cycle 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I
ng/mLPrednisolone
Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I1131 ± 223.92
SecondaryMedian Time to First Response - Phase II

Time to first response is the duartion of time required to achieve first response to treatment

Time frame:
up to 54 weeks
Reported as:
Median · Days
Median Time to First Response - Phase II
DaysPhase II - JNJ-26866138 1.3 mg/m2 Group
Median Time to First Response - Phase II51 (43 to 82)

Adverse events

Collected over 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - JNJ-26866138 0.7 mg/m2 Group—2/6 (33.3%)6/6 (100%)
Phase I - JNJ-26866138 1.0 mg/m2 Group—2/6 (33.3%)6/6 (100%)
Phase I - JNJ-26866138 1.3 mg/m2 Group—1/6 (16.7%)6/6 (100%)
Phase II - JNJ-26866138 1.3 mg/m2 Group—29/87 (33.3%)87/87 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 GroupPhase II - JNJ-26866138 1.3 mg/m2 Group
GlaucomaEye disorders1/60/60/60/87
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/60/60/60/87
RashSkin and subcutaneous tissue disorders0/60/61/61/87
Renal failureRenal and urinary disorders0/61/60/60/87
PyrexiaGeneral disorders0/61/60/60/87
Tumour lysis syndromeMetabolism and nutrition disorders0/60/60/62/87
HypoxiaRespiratory, thoracic and mediastinal disorders0/60/60/62/87
DiarrhoeaGastrointestinal disorders0/60/60/62/87
EnterocolitisGastrointestinal disorders0/60/60/62/87
Erythema multiformeSkin and subcutaneous tissue disorders0/60/60/62/87
Most frequent other events
Showing 10 of 99
Most frequent other events
EventPhase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I - JNJ-26866138 1.3 mg/m2 GroupPhase II - JNJ-26866138 1.3 mg/m2 Group
LeukopeniaBlood and lymphatic system disorders6/66/66/686/87
LymphopeniaBlood and lymphatic system disorders6/66/66/686/87
ThrombocytopeniaBlood and lymphatic system disorders6/66/65/686/87
NeutropeniaBlood and lymphatic system disorders6/66/66/684/87
DiarrhoeaGastrointestinal disorders2/63/66/656/87
NauseaGastrointestinal disorders1/62/66/648/87
PyrexiaGeneral disorders2/61/66/630/87
Decreased appetiteMetabolism and nutrition disorders5/62/65/650/87
Neuropathy peripheralNervous system disorders3/62/65/645/87
ConstipationGastrointestinal disorders4/62/65/645/87

Baseline characteristics

Age Continuous
Age Continuous(Years)Phase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I and II - JNJ-26866138 1.3 mg/m2 GroupTotal
Mean72.7 ± 9.268.5 ± 6.4770.9 ± 5.6870.9 ± 5.94
Age, Customized
Age, Customized(Participants)Phase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I and II - JNJ-26866138 1.3 mg/m2 GroupTotal
<65 years1135
>= 65 and <= 74 years256067
>=75 years302427
Sex: Female, Male
Sex: Female, Male(Participants)Phase I - JNJ-26866138 0.7 mg/m2 GroupPhase I - JNJ-26866138 1.0 mg/m2 GroupPhase I and II - JNJ-26866138 1.3 mg/m2 GroupTotal
Female335157
Male333642
08

Study locations

28 sites
  • Fukuoka, Japan
  • Hiroshima N/A, Japan
  • Hitachi, Japan
  • Isehara, Japan
  • Kamogawa, Japan
  • Kanazawa, Japan
  • Kawagoe, Japan
  • Kobe, Japan
  • Koto-Ku, Japan
  • Kumamoto, Japan
  • Kurashiki, Japan
  • Kurume, Japan
  • Kyoto, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Narita, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Osaka-Sayama, Japan
  • Sapporo, Japan
  • Shibukawa, Japan
  • Suita, Japan
  • Tokushima N/A, Japan
  • Tokyo, Japan
  • Toyama-City, Japan
  • Toyohashi, Japan
  • Utsunomiya, Japan
  • Yokohama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2009
First posted
Sep 29, 2009
Start
Jul 2008
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Dec 2, 2013
Last update
Dec 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00985959
Responsible party
Sponsor
First posted
Sep 29, 2009
Start date
Jul 2008
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Dec 2, 2013
Last update
Dec 2, 2013

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion